Mark Burge is an Endocrinology/Metabolic physician. OpenAlex indexes 212 publications with 4,189 citations (h-index 37); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1501 NE Medical Center Dr
Bend, OR 977016099
Telephone
541-382-4900Provider last certified this registry record 16 Dec 2025.
Clinical trials
- A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes
Sponsor: University of New Mexico
- Equine Assisted Psychotherapy for PTSD
Sponsor: University of New Mexico
- Efficacy Study of Mindfulness-Based Exercise for Posttraumatic Stress Disorder (PTSD)
Sponsor: University of New Mexico
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20253 payments
- Medtronic, Inc.Program year20252 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
72.5%GLP-1 receptor agonist25.5%Ozempic51%Trulicity41%Mounjaro8%Part D<11 patientsInsulin Analog20.8%Lantus Solostar31%Novolog Flexpen18%Basaglar Kwikpen U-10013%Lantus8%Humalog Kwikpen U-1007%Fiasp Flextouch7%Tresiba Flextouch U-1006%Toujeo Solostar6%Novolog5%Part D<11 patients+ 4 more classes in this area
Hormonal (systemic)
14.5%l-Thyroxine11.9%Levothyroxine Sodium83%Synthroid17%Part D≥59 patientsThyroid Hormone Synthesis Inhibitor2.6%Methimazole100%Part D≥15 patientsCardiovascular
7.4%Statin4.5%Atorvastatin Calcium74%Rosuvastatin Calcium26%Part D<11 patientsACE inhibitor1.7%Lisinopril100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”